Sign In

Communications of the ACM

ACM News

Doctors Wrestle With A.I. in Patient Care, Citing Lax Oversight

View as: Print Mobile App Share:
Dr. Nina Kottler, chief medical officer for clinical A.I. for Radiology Partners, has been leading a multiyear, multimillion-dollar effort to vet F.D.A.-cleared A.I. programs.

Doctors are raising more questions as they attempt to deploy the roughly 350 software tools that the U.S. Food and Drug Administration has cleared.

Credit: Laylah Amatullah Barrayn/The New York Times

In medicine, the cautionary tales about the unintended effects of artificial intelligence are already legendary.

There was the program meant to predict when patients would develop sepsis, a deadly bloodstream infection, that triggered a litany of false alarms. Another, intended to improve follow-up care for the sickest patients, appeared to deepen troubling health disparities.

Wary of such flaws, physicians have kept A.I. working on the sidelines: assisting as a scribe, as a casual second opinion and as a back-office organizer. But the field has gained investment and momentum for uses in medicine and beyond.

Within the Food and Drug Administration, which plays a key role in approving new medical products, A.I. is a hot topic. It is helping to discover new drugs. It could pinpoint unexpected side effects. And it is even being discussed as an aid to staff who are overwhelmed with repetitive, rote tasks.

From The New York Times
View Full Article



No entries found

Sign In for Full Access
» Forgot Password? » Create an ACM Web Account